- Home
- SEED vs RNAZ Comparison
SEED vs RNAZ Comparison
Compare SEED & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- RNAZ
- Stock Information
- Founded
- SEED 1997
- RNAZ 2016
- Country
- SEED China
- RNAZ United States
- Employees
- SEED N/A
- RNAZ N/A
- Industry
- SEED Farming/Seeds/Milling
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- RNAZ Health Care
- Exchange
- SEED Nasdaq
- RNAZ Nasdaq
- Market Cap
- SEED 6.9M
- RNAZ 6.1M
- IPO Year
- SEED N/A
- RNAZ 2021
- Fundamental
- Price
- SEED $0.99
- RNAZ $11.51
- Analyst Decision
- SEED
- RNAZ Strong Buy
- Analyst Count
- SEED 0
- RNAZ 1
- Target Price
- SEED N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- SEED 77.6K
- RNAZ 251.6K
- Earning Date
- SEED 06-26-2025
- RNAZ 08-22-2025
- Dividend Yield
- SEED N/A
- RNAZ N/A
- EPS Growth
- SEED N/A
- RNAZ N/A
- EPS
- SEED N/A
- RNAZ N/A
- Revenue
- SEED $12,910,081.00
- RNAZ N/A
- Revenue This Year
- SEED N/A
- RNAZ N/A
- Revenue Next Year
- SEED N/A
- RNAZ N/A
- P/E Ratio
- SEED N/A
- RNAZ N/A
- Revenue Growth
- SEED N/A
- RNAZ N/A
- 52 Week Low
- SEED $0.74
- RNAZ $6.15
- 52 Week High
- SEED $3.59
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- SEED 47.92
- RNAZ 56.95
- Support Level
- SEED $0.96
- RNAZ $10.16
- Resistance Level
- SEED $1.10
- RNAZ $12.10
- Average True Range (ATR)
- SEED 0.10
- RNAZ 1.40
- MACD
- SEED 0.00
- RNAZ -0.11
- Stochastic Oscillator
- SEED 26.67
- RNAZ 23.51
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.